Ohio is currently home to 3322 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Acuvue Oasys 1-Day Contact Lenses in New Wearers
NCT06333613
Recruiting
This is a multi-site, bilateral, dispensing, non-randomized, uncontrolled, unmasked, single arm study to evaluate visual acuity in neophytes.
Gender:
All
Ages:
Between 13 years and 39 years
Trial Updated:
04/23/2024
Locations: Procare Vision Centers, Granville, Ohio
Conditions: Visual Acuity
Register for Updates
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
Recruiting
The primary objective of this study is to assess the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the composite endpoint of all-cause mortality (ACM) and total cardiovascular (CV) clinical events.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/23/2024
Locations: Research Site, Cleveland, Ohio
Conditions: Transthyretin Amyloid Cardiomyopathy
Register for Updates
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
NCT06169124
Recruiting
This phase II trial tests how well darolutamide in combination with leuprolide acetate and exemestane works in treating patients with ovarian granulosa cell tumors that have come back after a period of improvement (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Leuprolide acetate is in a class of medications called gonadotropin-relea... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Miami Valley Hospital South, Centerville, Ohio
Conditions: Adult Ovarian Granulosa Cell Tumor
Register for Updates
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF
NCT06144632
Recruiting
The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Drug Refractory Paroxysmal Atrial Fibrillation
Register for Updates
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty
NCT06129539
Recruiting
The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants receiving gonadotropin-releasing hormone agonist (GnRHa) therapy for central precocious puberty (CPP).
Gender:
All
Ages:
Between 5 years and 8 years
Trial Updated:
04/23/2024
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Central Precocious Puberty
Register for Updates
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283
Recruiting
This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: James Cancer Hospital and Solove Research Institute, Columbus, Ohio
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Velocity Clinical Research, Beachwood, Ohio
Conditions: Obesity
Register for Updates
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844
Recruiting
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividin... Read More
Gender:
All
Ages:
70 years and above
Trial Updated:
04/23/2024
Locations: Strecker Cancer Center-Belpre, Belpre, Ohio
Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
NCT06049797
Recruiting
Hot flashes and night sweats (also known as vasomotor symptoms or VMS) are the most common symptoms which bother women in menopause. This study will follow women going through menopause who have hot flashes and night sweats that cause them bother. They will be starting a non-hormonal therapy prescribed by their healthcare provider (HCP) to treat these symptoms. The women will visit their HCP's office, research center, or both. They will receive prescriptions for the non-hormonal therapy from the... Read More
Gender:
Female
Ages:
Between 40 years and 75 years
Trial Updated:
04/23/2024
Locations: Axia Women's Health - Seven Hills Women's Health Centers - Anderson, Cincinnati, Ohio
Conditions: Hot Flashes
Register for Updates
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Bexley dermatology research, Bexley, Ohio
Conditions: Moderate Plaque Psoriasis
Register for Updates
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
NCT05980598
Recruiting
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years. This trial contains a safety run... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Ascendis Pharma Investigational Site, Canton, Ohio
Conditions: Head and Neck Neoplasms
Register for Updates
Open-Label Extension Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Uncontrolled Hypertension
NCT05968430
Recruiting
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Diabetes & Endocrinology Associates of Stark County, Canton, Ohio
Conditions: Hypertension
Register for Updates